ACRV vs. MACK, IMMP, PRQR, SYRS, NGM, VTGN, KNTE, ASMB, VTVT, and BYSI
Should you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Merrimack Pharmaceuticals (MACK), Immutep (IMMP), ProQR Therapeutics (PRQR), Syros Pharmaceuticals (SYRS), NGM Biopharmaceuticals (NGM), Vistagen Therapeutics (VTGN), Kinnate Biopharma (KNTE), Assembly Biosciences (ASMB), vTv Therapeutics (VTVT), and BeyondSpring (BYSI). These companies are all part of the "medical" sector.
Merrimack Pharmaceuticals (NASDAQ:MACK) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.
Merrimack Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.
Acrivon Therapeutics has a consensus target price of $21.38, suggesting a potential upside of 129.59%. Given Merrimack Pharmaceuticals' higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Merrimack Pharmaceuticals.
Acrivon Therapeutics' return on equity of -6.24% beat Merrimack Pharmaceuticals' return on equity.
Merrimack Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.
64.0% of Merrimack Pharmaceuticals shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 28.9% of Merrimack Pharmaceuticals shares are held by insiders. Comparatively, 7.3% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Merrimack Pharmaceuticals received 379 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Acrivon Therapeutics an outperform vote while only 67.00% of users gave Merrimack Pharmaceuticals an outperform vote.
In the previous week, Acrivon Therapeutics had 8 more articles in the media than Merrimack Pharmaceuticals. MarketBeat recorded 10 mentions for Acrivon Therapeutics and 2 mentions for Merrimack Pharmaceuticals. Merrimack Pharmaceuticals' average media sentiment score of 0.32 beat Acrivon Therapeutics' score of 0.30 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.
Summary
Acrivon Therapeutics beats Merrimack Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Acrivon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acrivon Therapeutics Competitors List
Related Companies and Tools
